Literature DB >> 15127426

Regression methods for covariate adjustment and subgroup analysis for non-censored cost-effectiveness data.

Andrew R Willan1, Andrew H Briggs, Jeffrey S Hoch.   

Abstract

The current interest in undertaking cost-effectiveness analyses alongside clinical trials has lead to the increasing availability of patient-level data on both the costs and effectiveness of intervention. In a recent paper, we show how cost-effectiveness analysis can be undertaken in a regression framework. In the current paper we develop a direct regression approach to cost-effectiveness analysis by proposing the use of a system of seemingly unrelated regression equations to provide a more general method for prognostic factor adjustment with emphasis on sub-group analysis. This more general method can be used in either an incremental cost-effectiveness or an incremental net-benefit approach, and does not require that the set of independent variables for costs and effectiveness be the same. Furthermore, the method can exhibit efficiency gains over unrelated ordinary least squares regression. Copyright 2003 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2004        PMID: 15127426     DOI: 10.1002/hec.843

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  94 in total

1.  The analysis of multinational cost-effectiveness data for reimbursement decisions: a critical appraisal of recent methodological developments.

Authors:  Andrea Manca; Mark J Sculpher; Ron Goeree
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

2.  Choice of statistical model for cost-effectiveness analysis and covariate adjustment: empirical application of prominent models and assessment of their results.

Authors:  Theodoros Mantopoulos; Paul M Mitchell; Nicky J Welton; Richard McManus; Lazaros Andronis
Journal:  Eur J Health Econ       Date:  2015-10-07

3.  The case for stratified cost-effectiveness analysis by baseline health-related QOL: theory and sensitivity analysis.

Authors:  Joseph Schaafsma
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

4.  Lessons from trial-based cost-effectiveness analyses of mental health interventions: why uncertainty about the outcome, estimate and willingness to pay matters.

Authors:  Jeffrey S Hoch; Carolyn S Dewa
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

5.  Value of information and pricing new healthcare interventions.

Authors:  Andrew R Willan; Simon Eckermann
Journal:  Pharmacoeconomics       Date:  2012-06-01       Impact factor: 4.981

6.  Cost-utility and cost-effectiveness of physical exercise during adjuvant chemotherapy.

Authors:  Hanna van Waart; Johanna M van Dongen; Wim H van Harten; Martijn M Stuiver; Rosalie Huijsmans; Jeannette A J H Hellendoorn-van Vreeswijk; Gabe S Sonke; Neil K Aaronson
Journal:  Eur J Health Econ       Date:  2017-10-30

7.  Progesterone to prevent miscarriage in women with early pregnancy bleeding: the PRISM RCT.

Authors:  Arri Coomarasamy; Hoda M Harb; Adam J Devall; Versha Cheed; Tracy E Roberts; Ilias Goranitis; Chidubem B Ogwulu; Helen M Williams; Ioannis D Gallos; Abey Eapen; Jane P Daniels; Amna Ahmed; Ruth Bender-Atik; Kalsang Bhatia; Cecilia Bottomley; Jane Brewin; Meenakshi Choudhary; Fiona Crosfill; Shilpa Deb; W Colin Duncan; Andrew Ewer; Kim Hinshaw; Thomas Holland; Feras Izzat; Jemma Johns; Mary-Ann Lumsden; Padma Manda; Jane E Norman; Natalie Nunes; Caroline E Overton; Kathiuska Kriedt; Siobhan Quenby; Sandhya Rao; Jackie Ross; Anupama Shahid; Martyn Underwood; Nirmala Vaithilingham; Linda Watkins; Catherine Wykes; Andrew W Horne; Davor Jurkovic; Lee J Middleton
Journal:  Health Technol Assess       Date:  2020-06       Impact factor: 4.014

8.  Doxycycline Added to Prednisolone in Outpatient-Treated Acute Exacerbations of COPD: A Cost-Effectiveness Analysis Alongside a Randomised Controlled Trial.

Authors:  Aureliano Paolo Finch; Patricia van Velzen; Gerben Ter Riet; Peter J Sterk; Jan M Prins; Judith E Bosmans
Journal:  Pharmacoeconomics       Date:  2019-05       Impact factor: 4.981

Review 9.  Acknowledging patient heterogeneity in economic evaluation : a systematic literature review.

Authors:  Janneke P C Grutters; Mark Sculpher; Andrew H Briggs; Johan L Severens; Math J Candel; James E Stahl; Dirk De Ruysscher; Albert Boer; Bram L T Ramaekers; Manuela A Joore
Journal:  Pharmacoeconomics       Date:  2013-02       Impact factor: 4.981

10.  Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT.

Authors:  Philip Hykin; A Toby Prevost; Sobha Sivaprasad; Joana C Vasconcelos; Caroline Murphy; Joanna Kelly; Jayashree Ramu; Abualbishr Alshreef; Laura Flight; Rebekah Pennington; Barry Hounsome; Ellen Lever; Andrew Metry; Edith Poku; Yit Yang; Simon P Harding; Andrew Lotery; Usha Chakravarthy; John Brazier
Journal:  Health Technol Assess       Date:  2021-06       Impact factor: 4.014

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.